Integrating explainable deep learning with multi-omics for screening progressive diagnostic biomarkers of hepatocellular carcinoma covering the “inflammation-cancer” transformation

Saiyu Li; Yiwen Zhang; Lifang Guan; Yijing Dong; Mingzhe Zhang; Qian Zhang; Huarong Xu; Wei Xiao; Zhenzhong Wang; Yan Cui; Qing Li

doi:10.1016/j.jpha.2025.101253

Volume 15 Issue 9

Sep. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2025 > 15(9): 101253

Saiyu Li, Yiwen Zhang, Lifang Guan, Yijing Dong, Mingzhe Zhang, Qian Zhang, Huarong Xu, Wei Xiao, Zhenzhong Wang, Yan Cui, Qing Li. Integrating explainable deep learning with multi-omics for screening progressive diagnostic biomarkers of hepatocellular carcinoma covering the “inflammation-cancer” transformation[J]. Journal of Pharmaceutical Analysis, 2025, 15(9): 101253. doi: 10.1016/j.jpha.2025.101253

Citation:

Saiyu Li, Yiwen Zhang, Lifang Guan, Yijing Dong, Mingzhe Zhang, Qian Zhang, Huarong Xu, Wei Xiao, Zhenzhong Wang, Yan Cui, Qing Li. Integrating explainable deep learning with multi-omics for screening progressive diagnostic biomarkers of hepatocellular carcinoma covering the “inflammation-cancer” transformation[J]. Journal of Pharmaceutical Analysis, 2025, 15(9): 101253. doi: 10.1016/j.jpha.2025.101253

Citation:

Saiyu Li, Yiwen Zhang, Lifang Guan, Yijing Dong, Mingzhe Zhang, Qian Zhang, Huarong Xu, Wei Xiao, Zhenzhong Wang, Yan Cui, Qing Li. Integrating explainable deep learning with multi-omics for screening progressive diagnostic biomarkers of hepatocellular carcinoma covering the “inflammation-cancer” transformation[J]. Journal of Pharmaceutical Analysis, 2025, 15(9): 101253. doi: 10.1016/j.jpha.2025.101253

PDF( 1190 KB)

Integrating explainable deep learning with multi-omics for screening progressive diagnostic biomarkers of hepatocellular carcinoma covering the “inflammation-cancer” transformation

doi: 10.1016/j.jpha.2025.101253

a. School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, China;
b. State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, 222001, China

Funds:

This work was supported by Liaoning Province Science and Technology Plan Project, China (Grant No.: 2022JH2/101300038), Liaoning Provincial Applied Basic Research Project, China (Grant No.: 2022020255-JH2/1013), the National Natural Science Foundation of China of China (Grant Nos.: 82104379/H3203 and 82104126/H3410), Liaoning Distinguished Professor Project (2017), Liaoning BaiQianWan Talents Program in 2019 (A-37), China, Liaoning key Research and Development Program (2018), China, the Natural Science Funds of Liaoning Province, China (Grant No.: 2021JH2/10300068), the Basic Scientific Research Project of Higher Education Department of Liaoning Province, China (Grant No.: LJ212410163036), and Educational Commission of Liaoning Province of China, China (Grant No.: LJ212410163026).

Received Date: Sep. 19, 2024
Accepted Date: Feb. 27, 2025
Rev Recd Date: Feb. 05, 2025
Publish Date: Sep. 30, 2025

Abstract

FullText(HTML)

References(5)

References

[1]	S. Chidambaranathan-Reghupaty, P.B. Fisher, D. Sarkar., Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification, Adv. Cancer Res. 149 (2021) 1-61.
[2]	P. Zheng, S. Sun, J. Wang, et al., Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis, Cell. Mol. Life Sci. 79 (2022), 66.
[3]	H. Wang, Y. Wang, X. Li, et al., Machine learning of plasma metabolome identifies biomarker panels for metabolic syndrome: Findings from the China Suboptimal Health Cohort, Cardiovasc. Diabetol. 21 (2022), 288.
[4]	Y. She, Z. Jin, J. Wu, et al., Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival, JAMA Netw. Open. 3 (2020), e205842.
[5]	C. Guo, Z. Liu, H. Fan, et al., Machine-learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis, Hepatology 81 (2024) 168-180.